Flu Is Increasing Right Now — And These Regions Are Seeing The Biggest Spikes

U.S. flu activity is rising sharply with CDC data for the week ending Dec. 6 showing high levels in New York, Colorado, New Jersey and Louisiana (New York City classified as “very high”); Hackensack Meridian Health reports ~30% flu test positivity compared with ~2–3% for COVID and RSV. The surge is driven by a mutated H3N2 strain accounting for roughly 85–86% of cases, with vaccine effectiveness estimated at ~30–50% for preventing adult hospitalization and ~70–75% in children, and last season saw about 400,000 hospitalizations—trends likely to pressure healthcare utilization, staffing and near‑term travel/leisure demand.

Analysis

Market structure: Acute H3N2 activity favors diagnostics (rapid tests), retail pharmacies, OTC consumer health and urgent-care operators while pressuring travel/leisure and hourly-labor–intensive services. Expect pricing power and order-replenishment revenue for diagnostics (short-cycle demand) and inventory drawdowns into January; airlines and restaurants face short-term revenue and staffing shocks that compress margins by a few percentage points if absenteeism rises >5-10% regionally.

Risk assessment: Immediate (days–weeks) risk is supply tightness for rapid tests/antivirals and localized hospital capacity stress; short-term (1–3 months) risk is higher absenteeism and litigation/regulatory scrutiny if pediatric deaths rise. Tail scenarios: a vaccine-resistant H3N2 causing school closures and >30% week-over-week hospitalizations would materially hit Q1 GDP growth and push safe-haven flows into Treasuries; hidden dependency is vaccine uptake heterogeneity by state.

Trade implications: Favor short-dated exposure to diagnostic and pharmacy stocks (30–90 day horizon) and defensive staples; rotate out of discretionary travel/airlines. Use pair trades to capture relative demand (long diagnostics/pharmacies, short airlines) and options to harvest elevated airline vols around holiday travel. Key catalysts: CDC hospitalization/positivity and weekly pediatric death reports — act quickly if those metrics cross defined thresholds.

Contrarian angles: Consensus underprices the medium-term upside to next-gen flu vaccines (mRNA incumbents) and overprices structural damage to airlines from a single-season surge. If CDC positivity does not sustain >20% nationally within 3 weeks, airlines should mean-revert; conversely, sustained shortages of tests into Feb would create follow-through gains for diagnostics and retail health.

Key Decisions for Investors

• Establish a 2.5% portfolio long position split 1.5% Abbott Laboratories (ABT) and 1.0% Quidel (QDEL) within 7 trading days to capture near-term test demand; target holding 4–8 weeks and take profits if combined move >20% or CDC national positivity falls below 10% for two consecutive weeks.
• Open a 2% long position in CVS Health (CVS) within 10 days to play elevated foot traffic/OTC sales; hedge with a 1.5% short position in American Airlines (AAL) (or buy AAL 60-day puts 12% OTM sized 1.0% of portfolio) to express relative strength of healthcare vs travel during peak season.
• Allocate 0.5–1.0% as a 6–12 month speculative long in Moderna (MRNA) to capture optionality on mRNA flu vaccine adoption; scale to 2% only if company data or regulatory guidance indicates >50% chance of accelerated commercial rollout.
• Set objective triggers to scale positions: increase long diagnostics/pharmacy exposure by +50% if CDC hospitalization rates rise >20% week-over-week or pediatric flu deaths are reported in ≥3 states within a 10-day window; cut exposure by 50% if national test positivity declines below 10% for two consecutive weeks.